Table 2.
Effect of adipokines on the composite endpoint of CV death, non-procedural MI and stroke.
| Outcome: CV Death/Non-Procedural MI/Stroke |
Unadjusted Model | Adjusted Model* | Final Fully Adjusted Model* |
|||
|---|---|---|---|---|---|---|
| Covariate | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P |
| Baseline Log leptin | 0.9 (0.8, 1.0) | .22 | 0.8 (0.7, 1.0) | .02 | 0.9 (0.8, 1.0) | .02 |
| Change from Baseline Log leptin | 0.8 (0.8, 1.0) | .01 | 0.8 (0.7, 0.9) | <.001 | 0.8 (0.7, 0.9) | <.001 |
| Baseline Log adiponectin | 1.2 (1.1, 1.3) | .001 | 1.2 (1.0, 1.3) | .01 | 1.2 (1.0, 1.4) | .01 |
| Change from Baseline Log adiponectin | 1.1 (1.0, 1.2) | .20 | 1.0 (0.9, 1.2) | .69 | 1.0 (0.9, 1.2) | .53 |
| Baseline Log MCP-1 | 1.1 (0.9, 1.2) | .35 | 0.9 (0.8, 1.1) | .34 | 0.9 (0.8, 1) | .14 |
| Change from Baseline Log MCP-1 | 1.1 (1, 1.3) | .19 | 1.0 (0.9, 1.2) | .60 | 1.0 (0.9, 1.2) | .84 |
| Baseline Log leptin/adiponectin | 0.9 (0.8, 1.0) | .01 | 0.8 (0.7, 0.9) | .001 | ||
| Change from Baseline Log leptin/adiponectin | 0.8 (0.8, 1.0) | .008 | 0.8 (0.7, 0.9) | .003 | ||
| Baseline Log leptin/BMI | 0.9 (0.8, 1.0) | .21 | 0.9 (0.8, 1.0) | .02 | ||
| Change from Baseline Log leptin/BMI | 0.9 (0.8, 1.0) | .09 | 0.8 (0.7, 0.9) | .003 | ||
| Baseline Log TNF-α | 1.4 (1.2, 1.5) | <.001 | 1.2 (1.1, 1.4) | <.001 | 1.1 (1.0, 1.3) | .01 |
| Change from Baseline Log TNF-α | 1.2 (1.1, 1.3) | <.001 | 1.2 (1.1, 1.3) | .002 | 1.2 (1.0, 1.3) | .02 |
| Baseline Log CRP | 1.4 (1.3, 1.6) | <.001 | 1.5 (1.3, 1.7) | <.001 | 1.4 (1.2, 1.6) | <.001 |
| Change from Baseline Log CRP | 1.2 (1.1, 1.4) | .003 | 1.3 (1.1, 1.5) | <.001 | 1.2 (1.1, 1.4) | .004 |
| Baseline Log IL-6 | 1.4 (1.3, 1.6) | <.001 | 1.3 (1.1, 1.5) | <.001 | 1.1 (0.9, 1.3) | .28 |
| Change from Baseline Log IL-6 | 1.1 (1.0, 1.3) | .04 | 1.1 (1.0, 1.3) | .10 | 1.0 (0.9, 1.2) | .82 |
Unadjusted and adjusted models contain only the baseline and change of one adipokine measure at a time, thus each major row is a different model. The adjusted models are adjusted for : age, sex, BMI, systolic blood pressure, left ventricular ejection fraction <50%, number of coronary vessels with ≥50% stenosis, prior revascularization, history of MI, history of stroke, HbA1c, low density lipoprotein, high density lipoprotein and triglyceride levels, micro- and macro- albuminuria, glomerular filtration rate, current smoking status and randomization groups. All adjustment variables were measured at baseline, with the exception of BMI, which was updated each time when adipokine measures were available. The final fully adjusted model is a joint model, with all adipokines in the final model column in one model. HR reflects a one SD change in the sex standardized log value of the adipokine measure on the composite endpoint.
20 participants were excluded due to missing baseline BMI values